Gregory L Calligaro1, Lynn S Zijenah2, Jonathan G Peter3, Grant Theron4, Virginia Buser5, Ruth McNerney5, Wilbert Bara6, Tsitsi Bandason7, Ureshnie Govender5, Michele Tomasicchio5, Liezel Smith5, Bongani M Mayosi8, Keertan Dheda9. 1. Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; Lung Infection and Immunity Unit, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. 2. Department of Immunology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. 3. Institute of Infectious Diseases and Molecular Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; Division of Clinical Immunology and Allergology, Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. 4. Lung Infection and Immunity Unit, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; DST/NRF of Excellence for Biomedical Tuberculosis Research, and MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa. 5. Lung Infection and Immunity Unit, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. 6. Mabvuku Polyclinic, Zimbabwe Ministry of Health and Child Care, Harare, Zimbabwe. 7. Biomedical and Research Training Institute, Harare, Zimbabwe. 8. Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa. 9. Division of Pulmonology, Department of Medicine and UCT Lung Institute, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; Institute of Infectious Diseases and Molecular Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; Lung Infection and Immunity Unit, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe; Division of Clinical Immunology and Allergology, Department of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. Electronic address: keertan.dheda@uct.ac.za.
Abstract
BACKGROUND: Inadequate case detection results in high levels of undiagnosed tuberculosis in sub-Saharan Africa. Data for the effect of new diagnostic tools when used for community-based intensified case finding are not available, so we investigated whether the use of sputum Xpert-MTB/RIF and the Determine TB LAM urine test in two African communities could be effective. METHODS: In a pragmatic, randomised, parallel-group trial with individual randomisation stratified by country, we compared sputum Xpert-MTB/RIF, and if HIV-infected, the Determine TB LAM urine test (novel diagnostic group), with laboratory-based sputum smear microscopy (routine diagnostic group) for intensified case findingin communities with high tuberculosis and HIV prevalence in Cape Town, South Africa, and Harare, Zimbabwe. Participants were randomly assigned (1:1) to these groups with computer-generated allocation lists, using culture as the reference standard. In Cape Town, participants were randomised and tested at an Xpert-equipped mobile van, while in Harare, participants were driven to a local clinic where the same diagnostic tests were done. The primary endpoint was the proportion of culture-positive tuberculosis cases initiating tuberculosis treatment in each study group at 60 days. This trial is registered at ClinicalTrials.gov, number NCT01990274. FINDINGS:Between Oct 18, 2013, and March 31, 2015, 2261 individuals were screened and 875 (39%) of these met the criteria for diagnostic testing. 439 participants were randomly assigned to the novel group and 436 to the routine group. 74 (9%) of 875 participants had confirmed tuberculosis. If late culture-based treatment initiation was excluded, more patients with culture-positive tuberculosis were initiated on treatment in the novel group at 60 days (36 [86%] of 42 in the novel group vs 18 [56%] of 32 in the routine group). Thus the difference in the proportion initiating treatment between groups was 29% (95% CI 9-50, p=0·0047) and 53% more patients initiated therapy in the novel diagnostic group than in the routine diagnostic group. One culture-positive patient was treated based only on a positive LAM test. INTERPRETATION: Compared with traditional tools, Xpert-MTB/RIF for community-based intensified case finding in HIV and tuberculosis-endemic settings increased the proportion of patients initiating treatment. By contrast, urine LAM testing was not found to be useful for intensive case finding in this setting. FUNDING: European and Developing Countries Clinical Trials Partnership and South African Medical Research Council.
RCT Entities:
BACKGROUND: Inadequate case detection results in high levels of undiagnosed tuberculosis in sub-Saharan Africa. Data for the effect of new diagnostic tools when used for community-based intensified case finding are not available, so we investigated whether the use of sputum Xpert-MTB/RIF and the Determine TB LAM urine test in two African communities could be effective. METHODS: In a pragmatic, randomised, parallel-group trial with individual randomisation stratified by country, we compared sputum Xpert-MTB/RIF, and if HIV-infected, the Determine TB LAM urine test (novel diagnostic group), with laboratory-based sputum smear microscopy (routine diagnostic group) for intensified case finding in communities with high tuberculosis and HIV prevalence in Cape Town, South Africa, and Harare, Zimbabwe. Participants were randomly assigned (1:1) to these groups with computer-generated allocation lists, using culture as the reference standard. In Cape Town, participants were randomised and tested at an Xpert-equipped mobile van, while in Harare, participants were driven to a local clinic where the same diagnostic tests were done. The primary endpoint was the proportion of culture-positive tuberculosis cases initiating tuberculosis treatment in each study group at 60 days. This trial is registered at ClinicalTrials.gov, number NCT01990274. FINDINGS: Between Oct 18, 2013, and March 31, 2015, 2261 individuals were screened and 875 (39%) of these met the criteria for diagnostic testing. 439 participants were randomly assigned to the novel group and 436 to the routine group. 74 (9%) of 875 participants had confirmed tuberculosis. If late culture-based treatment initiation was excluded, more patients with culture-positive tuberculosis were initiated on treatment in the novel group at 60 days (36 [86%] of 42 in the novel group vs 18 [56%] of 32 in the routine group). Thus the difference in the proportion initiating treatment between groups was 29% (95% CI 9-50, p=0·0047) and 53% more patients initiated therapy in the novel diagnostic group than in the routine diagnostic group. One culture-positive patient was treated based only on a positive LAM test. INTERPRETATION: Compared with traditional tools, Xpert-MTB/RIF for community-based intensified case finding in HIV and tuberculosis-endemic settings increased the proportion of patients initiating treatment. By contrast, urine LAM testing was not found to be useful for intensive case finding in this setting. FUNDING: European and Developing Countries Clinical Trials Partnership and South African Medical Research Council.
Authors: Grant Theron; Jason Limberis; Rouxjeane Venter; Liezel Smith; Elize Pietersen; Aliasgar Esmail; Greg Calligaro; Julian Te Riele; Marianna de Kock; Paul van Helden; Tawanda Gumbo; Taane G Clark; Kevin Fennelly; Robin Warren; Keertan Dheda Journal: Nat Med Date: 2020-06-29 Impact factor: 53.440
Authors: Andrew Medina-Marino; Lindsey de Vos; Dana Bezuidenhout; Claudia M Denkinger; Samuel G Schumacher; Sanghyuk S Shin; Wendy Stevens; Grant Theron; Martie van der Walt; Joseph Daniels Journal: Trop Med Int Health Date: 2021-01-04 Impact factor: 2.622
Authors: V R Rivera; M-A Jean-Juste; S C Gluck; H T Reeder; J Sainristil; P Julma; M Peck; P Joseph; O Ocheretina; C Perodin; R Secours; M Duran-Mendicuti; L Hashiguchi; P Y Cremieux; S P Koenig; J W Pape Journal: Int J Tuberc Lung Dis Date: 2017-11-01 Impact factor: 2.373
Authors: Stephanie Bjerrum; Ian Schiller; Nandini Dendukuri; Mikashmi Kohli; Ruvandhi R Nathavitharana; Alice A Zwerling; Claudia M Denkinger; Karen R Steingart; Maunank Shah Journal: Cochrane Database Syst Rev Date: 2019-10-21
Authors: Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman Journal: Clin Microbiol Rev Date: 2018-07-18 Impact factor: 26.132
Authors: David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart Journal: Cochrane Database Syst Rev Date: 2019-06-07
Authors: Andrea da Silva Santos; Roberto Dias de Oliveira; Everton Ferreira Lemos; Fabiano Lima; Ted Cohen; Olivia Cords; Leonardo Martinez; Crhistinne Gonçalves; Albert Ko; Jason R Andrews; Julio Croda Journal: Clin Infect Dis Date: 2021-03-01 Impact factor: 9.079
Authors: Adrienne E Shapiro; Jennifer M Ross; Mandy Yao; Ian Schiller; Mikashmi Kohli; Nandini Dendukuri; Karen R Steingart; David J Horne Journal: Cochrane Database Syst Rev Date: 2021-03-23